Home - Products - Others - Other Targets - 2-(Chloromethyl)Imidazo[1,2-A]Pyridine

2-(Chloromethyl)Imidazo[1,2-A]Pyridine

CAS No. 57892-76-9

2-(Chloromethyl)Imidazo[1,2-A]Pyridine( —— )

Catalog No. M37013 CAS No. 57892-76-9

2-(Chloromethyl)imidazo[1,2-a]pyridine has potential anthelmintic activity and can be used to synthesize active compounds.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 30 In Stock
50MG 43 In Stock
100MG 63 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    2-(Chloromethyl)Imidazo[1,2-A]Pyridine
  • Note
    Research use only, not for human use.
  • Brief Description
    2-(Chloromethyl)imidazo[1,2-a]pyridine has potential anthelmintic activity and can be used to synthesize active compounds.
  • Description
    2-(Chloromethyl)imidazo[1,2-a]pyridine has potential anthelmintic activity and can be used to synthesize active compounds.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    57892-76-9
  • Formula Weight
    166.61
  • Molecular Formula
    C8H7ClN2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ClCc1cn2ccccc2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Canthaxanthin

    Canthaxanthin is a red-orange carotenoid that belongs to the xanthophyll group.

  • OVA Peptide 257-264 ...

    OVA Peptide 257-264 2TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.

  • Concizumab

    Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.